SLU-PP-332 | 1,5 Mg/ 3 ml Pen

SLU-PP-332 is an investigational mitochondrial/energy-focused research compound explored for its role in oxidative metabolism and endurance-related bioenergetic endpoints. It is commonly discussed in the context of nuclear receptor signaling that influences mitochondrial biogenesis programs, substrate utilization, and fatigue-resistance markers in preclinical models. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.

Supports

Mitochondrial energy output frameworks associated with oxidative phosphorylation efficiency markers.
Fatigue-resistance endpoints tracked through muscle bioenergetic and recovery readouts in models.
Metabolic flexibility context linked to fatty acid oxidation and substrate-shift signaling.
Mitochondrial biogenesis programs associated with PGC-1α/NRF/TFAM pathway readouts.
Oxidative-stress balance markers monitored via ROS and redox-related assay endpoints.

Description

SLU-PP-332 is a research compound frequently described as an agonist within nuclear receptor signaling frameworks that regulate mitochondrial function and systemic energy utilization. In experimental design, it is positioned to study how transcriptional control of oxidative metabolism affects endurance phenotypes, fuel preference (fat vs. glucose utilization), and mitochondrial adaptation markers in skeletal muscle and metabolic tissues.

Across preclinical models, SLU-PP-332 is commonly framed around increased oxidative capacity and shifts toward more oxidative muscle fiber characteristics, alongside changes in mitochondrial density and respiration-related readouts. Studies often measure downstream markers linked to mitochondrial biogenesis and electron transport chain activity, as well as substrate-oxidation signals that reflect metabolic reprogramming under controlled conditions.

Reported observations are model- and endpoint-dependent. This product is presented for research and educational context only and is not marketed as an approved therapeutic product.

Clinical Status

SLU-PP-332 is primarily evaluated in preclinical and in vitro settings focused on mitochondrial performance, endurance physiology, and metabolic signaling. It is not presented here as an approved therapeutic product, and outcomes can vary substantially by study design, protocol variables, and model selection.

Evidence type:
Human RCT ☐ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

SLU-PP-332 is commonly discussed as an activator of nuclear receptor pathways associated with mitochondrial biogenesis and oxidative metabolism programs. In model systems, downstream readouts often include increased expression of regulators such as PGC-1α, NRF-1, and TFAM, alongside changes in mitochondrial transcription and electron transport chain component markers. These adaptations are used to frame hypotheses around improved oxidative phosphorylation capacity and sustained ATP availability in endurance settings.

Preclinical work also describes shifts in β-oxidation signaling and metabolic flexibility markers, sometimes discussed alongside AMPK-related pathway readouts. Reported changes in ROS/oxidative-load metrics are frequently evaluated in parallel to assess mitochondrial efficiency and oxidative stress balance under experimental conditions.

Benefits

Selective PPARδ Activation and Metabolic Optimization:
Slu-pp-332 is studied as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), a key regulator of lipid and glucose metabolism. By activating PPARδ pathways, it enhances energy utilization in skeletal muscle and promotes a metabolic shift from glucose to fatty acid oxidation, making it an advanced subject in mitochondrial and endurance research.
Enhanced Fat Oxidation and Energy Efficiency:
Preclinical data indicate that Slu-pp-332 increases fatty acid β-oxidation and mitochondrial respiration, resulting in improved ATP generation and endurance performance. This metabolic reprogramming supports greater energy efficiency and resilience during prolonged activity, aligning it with research into metabolic performance enhancement and fatigue resistance.
Improved Muscle Endurance and Exercise Capacity:
Slu-pp-332 has been shown to improve exercise performance by upregulating genes associated with oxidative muscle fibers and mitochondrial density. This shift enhances muscle fatigue resistance and promotes endurance phenotypes, making it of interest in research exploring athletic performance and cellular energy optimization.
Reduction of Fat Accumulation and Weight Gain:
In animal studies, Slu-pp-332 administration has resulted in decreased body fat accumulation even under high-fat dietary conditions. Its mechanism involves elevated fatty acid catabolism and reduced lipogenesis, supporting its study as a potential modulator of weight management and metabolic balance.
Improvement of Insulin Sensitivity and Glucose Tolerance:
Through its action on PPARδ receptors in muscle and liver tissue, Slu-pp-332 enhances glucose uptake and insulin sensitivity. Research shows improved glycemic control and lower fasting glucose levels in metabolic models, making it relevant in studies addressing insulin resistance and glucose homeostasis.
Enhanced Mitochondrial Biogenesis and Cellular Respiration:
Activation of PPARδ by Slu-pp-332 stimulates PGC-1α signaling, leading to the creation of new mitochondria and improved respiratory chain activity. This boost in mitochondrial number and function supports sustained cellular energy production and resilience under oxidative or metabolic stress conditions.
Support for Muscle Fiber Transformation:
Slu-pp-332 promotes a shift toward oxidative type I muscle fibers known for higher endurance and fatigue resistance. This fiber-type remodeling is driven by enhanced mitochondrial enzyme expression and energy utilization, providing a strong foundation for research into endurance training and muscle adaptation mechanisms.
Anti-Inflammatory and Antioxidant Properties:
Research shows that PPARδ activation by Slu-pp-332 reduces pro-inflammatory cytokine expression and upregulates antioxidant defenses, including superoxide dismutase and catalase. These effects protect tissues from inflammation-induced oxidative damage, supporting applications in metabolic and cardiovascular research.
Protection of Liver and Metabolic Organs:
In hepatic models, Slu-pp-332 reduces lipid accumulation and oxidative stress while improving liver enzyme markers. These hepatoprotective effects are attributed to enhanced β-oxidation and reduced triglyceride synthesis, highlighting its potential role in non-alcoholic fatty liver disease and metabolic syndrome research.
Enhanced Cognitive and Neural Energy Metabolism:
Emerging data suggest that Slu-pp-332 may improve neuronal energy metabolism by increasing mitochondrial density and lipid utilization in brain tissue. This effect supports cognitive performance and neural protection under metabolic stress, forming a promising research link between PPARδ activation and neuroenergetics.
Synergy with Mitochondrial Peptides and NAD+ Precursors:
When combined with mitochondrial modulators such as MOTS-c, SS-31, or NAD+, Slu-pp-332 enhances oxidative phosphorylation and systemic energy turnover. This synergistic relationship is being explored in models targeting longevity, endurance, and metabolic resilience optimization.
Potential in Longevity and Anti-Aging Research:
Through sustained activation of metabolic and mitochondrial pathways, Slu-pp-332 supports cellular rejuvenation and energy preservation associated with extended healthspan. Its influence on lipid metabolism, oxidative balance, and mitochondrial efficiency makes it a key compound in aging and vitality-related peptide research.

Research Data

Study/model	Reported effect
Mouse endurance models	↑ Running time to exhaustion (+35%), ↑ ATP levels in muscle tissue
In vitro mitochondrial assays	↑ OXPHOS complex activity (I-IV), ↓ ROS leakage
Rat fatigue recovery studies	↓ Lactate accumulation, ↑ glycogen resynthesis post-exercise
Cellular oxidative stress models	↑ GSH:GSSG ratio, ↓ lipid peroxidation markers
AMPK activation assays	↑ p-AMPK and PGC-1α expression, ↑ mitochondrial density
High-fat diet mouse models	↓ Fat accumulation, ↑ β-oxidation enzyme expression
Neuronal culture models	↑ Mitochondrial membrane potential, ↓ oxidative apoptosis

Stack Suggestions

In extended experimental designs, SLU-PP-332 is sometimes paired with:

NAD+ (redox and mitochondrial-context frameworks commonly monitored in energy studies)
SS-31 (mitochondrial stress and membrane-stability frameworks)
MOTS-c (metabolic signaling context in endurance-oriented study designs)
5-Amino-1MQ (metabolic flux and lipid-handling frameworks where applicable)

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

Slu-pp-332, as a research compound, may induce side effects in experimental models, primarily related to its metabolic activation. These reactions are generally mild and dose-dependent via oral administration. Monitoring is key in protocols.

Fatigue: Temporary energy fluctuations during adaptation.
Gastrointestinal Upset: Mild nausea or diarrhea at higher doses.
Headache: Occasional, possibly from metabolic shifts.
Muscle Cramps: Rare, linked to enhanced activity.
Hormonal Changes: Potential minor estrogen-related effects, though non-steroidal.

It is crucial to note that most side effects are transient. No serious adverse events reported in preclinical; long-term safety unknown.

Scientific References

Cautions

For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
Discontinue use if sensitivity occurs.

Variantes de producto

¡Disponible! Listo para enviar

Pairs well with

In stock!

Complimentary shipping & returns

SLU-PP-332 | 1,5 Mg/ 3 ml Pen

FAQs

Read our FAQs page to find more

Do I need a prescription to order?

No prescription is required to order. However, we recommend consulting a healthcare professional before starting any injectable therapy.

How should I store my products?

Store unopened products in a cool, dry place. Refrigerate as instructed after opening.

Are the peptide pens pre-mixed?

Yes. Our peptide pens are pre-mixed and ready to use. They are formulated for convenience and consistent dosing without the need for reconstitution.

Are these products suitable for everyone?

These products are intended for responsible adult use. Individual suitability varies depending on medical history, medications, and overall health status. Consulting a qualified medical professional before use is essential.

Are these products intended for medical treatment?

These products are not intended to diagnose, treat, cure, or prevent any disease. They are offered within the scope of applicable regulations and should be used responsibly.